Literature DB >> 11839666

Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer.

Toru Onita1, Ping Guang Ji, Jim W Xuan, Hideki Sakai, Hiroshi Kanetake, Patrick H Maxwell, Guo-Hua Fong, Manal Y Gabril, Madeleine Moussa, Joseph L Chin.   

Abstract

Endothelial Per-ARNT-Sim (PAS) domain protein-1 (EPAS-1)/hypoxia-inducible factor-2alpha (HIF-2alpha) is a member of the basic helix-loop-helix/PAS domain protein family and is considered to be an endothelial-specific, hypoxia-inducible transcription factor. Because hypoxia is a fundamental element of tumor biology determining clinical outcome, we performed an immunohistochemical study of EPAS-1 expression in a cohort of bladder cancer cases and assessed the possible correlation of EPAS-1 expression with tumor hypoxia and growth. In the 67 cases (37 radical cystectomy and 30 transurethral resection) studied, overexpression of EPAS-1/HIF-2alpha protein was not found in cancer cells or in normal tissues but was mostly found in stroma around cancer cells, and strong positive staining was noted in perinecrotic regions. The perinecrotic/tumorous expression of EPAS-1/HIF-2alpha was correlated statistically with higher histological grade (P < 0.001), advanced pathological T stage (P < 0.001), and presence of necrosis (P < 0.001). A parallel immunohistochemical analysis of a marker gene of vascular endothelial growth factor demonstrated its positive correlation with tumor grade, stage, and EPAS-1/HIF-2alpha overexpression, supporting the correlation of EPAS-1/HIF-2alpha up-regulation with tumor angiogenesis. To further clarify the relationship between hypoxia and vascularity in the perinecrotic/tumorous area with EPAS-1/HIF-2alpha expression, tissue microvessel density (MVD) was assessed. No significant correlation (P = 0.442) was found between EPAS-1/HIF-2alpha expression and MVD if the 67 tumors of different stages were all included. However, EPAS-1/HIF-2alpha-positive cases had lower MVD than EPAS-1/HIF-2alpha-negative cases (P = 0.001) if only invasive cancer cases were analyzed. In addition, in all EPAS-1/HIF-2alpha-positive staining cases, EPAS-1/HIF-2alpha-positive foci had lower MVD than EPAS-1/HIF-2alpha-negative foci (P < 0.001). Finally, using serial sections, the location of EPAS-1/HIF 2alpha expression was identified mainly in tumor-associated macrophage (TAM) as well as in some fibroblast cells. Focal TAM infiltration was identified at a higher level in EPAS-1-positive cases than EPAS-1-negative cases (P < 0.001). This is the first clinical report suggesting that hypoxia-induced, perinecrotic EPAS-1/HIF-2alpha expression is correlated with tumor progression and angiogenesis at higher grade and stage through focal TAM infiltration in invasive bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839666

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  Modulation of gene expression in MHCC97 cells by interferon alpha.

Authors:  Wei-Zhong Wu; Hui-Chuan Sun; Lu Wang; Jie Chen; Kang-Da Liu; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

Review 2.  Immunological hallmarks of stromal cells in the tumour microenvironment.

Authors:  Shannon J Turley; Viviana Cremasco; Jillian L Astarita
Journal:  Nat Rev Immunol       Date:  2015-10-16       Impact factor: 53.106

3.  Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.

Authors:  Gabriela R Passos; Juliana A Camargo; Karen L Ferrari; Mário J A Saad; Amilcar C de Mattos; Leonardo O Reis
Journal:  Med Oncol       Date:  2017-12-04       Impact factor: 3.064

Review 4.  Tumor macrophage redox and effector mechanisms associated with hypoxia.

Authors:  Michael Graham Espey
Journal:  Free Radic Biol Med       Date:  2006-09-16       Impact factor: 7.376

5.  Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma.

Authors:  Sébastien Le Jan; Céline Amy; Aurélie Cazes; Catherine Monnot; Noël Lamandé; Judith Favier; Josette Philippe; Mathilde Sibony; Jean-Marie Gasc; Pierre Corvol; Stéphane Germain
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

6.  Beclin 1 deficiency is associated with increased hypoxia-induced angiogenesis.

Authors:  Seon-Jin Lee; Hong-Pyo Kim; Yang Jin; Augustine M K Choi; Stefan W Ryter
Journal:  Autophagy       Date:  2011-08-01       Impact factor: 16.016

7.  CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis.

Authors:  Iñigo Espinosa; Badreddin Edris; Cheng-Han Lee; Hong Wei Cheng; C Blake Gilks; Yuzhuo Wang; Kelli D Montgomery; Sushama Varma; Rui Li; Robert J Marinelli; Robert B West; Torsten Nielsen; Andrew H Beck; Matt van de Rijn
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

8.  Hypoxia, angiogenesis and apoptosis markers in locally advanced rectal cancer.

Authors:  George E Theodoropoulos; Andreas C Lazaris; Vasilios E Theodoropoulos; Kalliopi Papatheodosiou; Maria Gazouli; John Bramis; Efstratios Patsouris; Dimitrios Panoussopoulos
Journal:  Int J Colorectal Dis       Date:  2005-07-29       Impact factor: 2.571

9.  Hypoxia-Inducible Factor α Subunits Regulate Tie2-Expressing Macrophages That Influence Tumor Oxygen and Perfusion in Murine Breast Cancer.

Authors:  Kayla J Steinberger; Mary A Forget; Andrey A Bobko; Nicole E Mihalik; Marieta Gencheva; Julie M Roda; Sara L Cole; Xiaokui Mo; E Hannah Hoblitzell; Randall Evans; Amy C Gross; Leni Moldovan; Clay B Marsh; Valery V Khramstov; Timothy D Eubank
Journal:  J Immunol       Date:  2020-09-16       Impact factor: 5.422

10.  Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors.

Authors:  Judith Favier; Pierre-François Plouin; Pierre Corvol; Jean-Marie Gasc
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.